Výsledky vyhledávání - "Sidney Hsieh"

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Autor: Ssucheng J. Hsu, Hsu-Ping Kuo, Darrin M. Beaupre, Sidney Hsieh, Mint Sirisawad, Matthias Versele, Mutiah Apatira, Chun-Te Chen, Betty Y. Chang, Karl J. Schweighofer, Leo W. K. Cheung, Scott A. Ezell, Karl Eckert

Publikováno v: Molecular Cancer Therapeutics. 16:1246-1256

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are the most prevalent B-lymphocyte neoplasms in which abnormal activation of the Bruton tyrosine kinase (BTK)–mediated B-cell receptor signaling pathway contributes to pathogenesis. Ibr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b59b101b1465894ef664fdefcb0d95
https://doi.org/10.1158/1535-7163.mct-16-0555

Zobrazit plný text záznamu

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma

Autor: Hsu-Ping, Kuo, Scott A, Ezell, Sidney, Hsieh, Karl J, Schweighofer, Leo Wk, Cheung, Shiquan, Wu, Mutiah, Apatira, Mint, Sirisawad, Karl, Eckert, Yu, Liang, Jeff, Hsu, Chun-Te, Chen, Darrin, Beaupre, Betty Y, Chang

Publikováno v: American journal of cancer research. 6(11)

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (AB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2431887dee95e294c159dfc53bf28a1d
https://pubmed.ncbi.nlm.nih.gov/27904766

Zobrazit plný text záznamu

Abstract 4197: Interaction of B lymphoma cells with the microenvironment affects ibrutinib sensitivity

Autor: Karl J. Schweighofer, Betty Chang, Kamaldeep Dhami, Shiquan Wu, Jing Liu, Leo W. K. Cheung, Mint Sirisawad, Jeff Hsu, Hsu-Ping Kuo, Kevin A. Kwei, Chi-Ling Fu, Chia-Lin Hsu, Karl Eckert, Mutiah Apatira, Hugh Wang, Chun-Te Chen, Sidney Hsieh

Publikováno v: Cancer Research. 77:4197-4197

Introduction: The cellular microenvironment plays a key role in the pathogenesis of B-cell malignancies (Amé-Thomas, Blood 2007; Podar, Leukemia 2009). Bone marrow stromal cell interactions can provide survival signals to CLL cells (Kurtova, Blood 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::afde9c343b20af2dc69d08a260ef7d04
https://doi.org/10.1158/1538-7445.am2017-4197

Zobrazit plný text záznamu

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Autor: Jennifer Whang, Yujun Huang, Betty Chang, Sidney Hsieh, Mint Sirisawad, Hsu-Ping Kuo

Publikováno v: Blood. 128:4140-4140

Background: Ibrutinib, a first-in-class, once-daily oral inhibitor of Bruton's tyrosine kinase (BTK), is indicated by the US FDA for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, including patients with delet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::926030a3a8b226194702dbfd3becd644
https://doi.org/10.1182/blood.v128.22.4140.4140

Zobrazit plný text záznamu

Abstract 3072: Combination of ibrutinib and corticosteroids in B-cell non-Hodgkin lymphomas (NHL)

Autor: Shiquan Wu, Darrin M. Beaupre, Betty Chang, Sidney Hsieh, Yu Liang, Karl J. Schweighofer, Leo Cheung, Chun-Te Chen, Karl Eckert, Mint Sirisawad, Jeff Hsu, Hsu-Ping Kuo, Mutiah Apatira

Publikováno v: Cancer Research. 76:3072-3072

Introduction: The B-cell receptor (BCR) signaling pathway is a major driver in the pathogenesis of B-cell malignancies. A vast array of BCR-associated kinases have emerged as rational therapeutic targets, including Bruton's tyrosine kinase (BTK), whi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6e7fc8d21f0f591359931a9f86443af
https://doi.org/10.1158/1538-7445.am2016-3072

Zobrazit plný text záznamu

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Autor: Karl J. Schweighofer, Mint Sirisawad, Karl Eckert, Sidney Hsieh, Shiquan Wu, Betty Y. Chang, Yu Liang, Jeff Hsu, Leo Cheung, Mutiah Apatira, Hsu-Ping Kuo

Publikováno v: Blood. 126:699-699

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for roughly 30% of newly diagnosed cases in the United States (US). DLBCL is a heterogeneous lymphoma, including the activated B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca15952dd247065769ba1715dc56fccc
https://doi.org/10.1182/blood.v126.23.699.699

Zobrazit plný text záznamu

Abstract 2598: Synergistic effect of ibrutinib and inhibitors targeting TLR signaling in ABC subtype of diffuse large B-Cell lymphoma

Autor: Hsu-Ping Kuo, Sidney Hsieh, Betty Chang

Publikováno v: Cancer Research. 75:2598-2598

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent B-lymphocyte neoplasm (Morton, Blood 2006). The activated B-cell (ABC) subtype is associated with poorer prognosis (Lenz, NEJM 2008). Over 20% of ABC-DLBCL cases have mutations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a1e8bf4d60124f0a21a6eb34c1dfef6
https://doi.org/10.1158/1538-7445.am2015-2598

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání